1, 2, and 3 are prepared with the appropriate amounts of a JNK inhibitor, such as any one of the JNK inhibitors described herein, and medium chain triglycerides (CRODAMOL, GTCC-LQ-(MV), PhEur) as shown in the below table (Table C).Formulations The formulations are prepared by adding the target weight percentage of any one of the JNK inhibitors described herein to the appropriate amount of medium chain triglyceride for a total volume of about 100 mL
These markings explain syringe capacity and measurement lines, not medication strength or dose
Research shows that GHK-Cu can modulate the expression of over 4,000 human genes involved in tissue repair and anti-inflammatory processes, essentially helping to reset gene expression to a healthier, more youthful state
To track intracellular persister cells in vivo, we constructed inducible S
Theyre safe and easy to administer